
Bialoom is a deep tech start-up based in Nicosia, Cyprus, focused on revolutionizing diagnostics through its proprietary silicon plasmo-photonic biosensor technology. The company aims to develop diagnostic tools for early diagnosis and treatment of acute infections at the point of need, utilizing affordable biochips embedded in disposable cartridges. Their multi-functional biochip can quantify complex biomarker signatures from patient blood, enabling faster and evidence-based diagnosis and treatment of severe infections. Bialoom differentiates itself with super-sensitive detection capabilities, low-cost manufacturing, and a commitment to partnerships in AI and machine learning to enhance diagnostic outcomes. With a vision to become a global leader in diagnostics, Bialoom is positioned to address significant healthcare challenges.

Bialoom is a deep tech start-up based in Nicosia, Cyprus, focused on revolutionizing diagnostics through its proprietary silicon plasmo-photonic biosensor technology. The company aims to develop diagnostic tools for early diagnosis and treatment of acute infections at the point of need, utilizing affordable biochips embedded in disposable cartridges. Their multi-functional biochip can quantify complex biomarker signatures from patient blood, enabling faster and evidence-based diagnosis and treatment of severe infections. Bialoom differentiates itself with super-sensitive detection capabilities, low-cost manufacturing, and a commitment to partnerships in AI and machine learning to enhance diagnostic outcomes. With a vision to become a global leader in diagnostics, Bialoom is positioned to address significant healthcare challenges.
Location: Nicosia, Cyprus (Engomi)
Founded: 2018
Core technology: Silicon plasmo-photonic biosensor (silicon photonics + plasmonics)
Product focus: Multi-functional biochip in disposable cartridge for point-of-care in-vitro diagnostics
Team size: 8 employees
Total funding (reported): 652847 USD
Point-of-care in-vitro diagnostics for early diagnosis and treatment of acute infections
2018
Biotechnology
Last listed round shown as a Grant in April 2020.
Horizon 2020 grant agreement No. 888337 (SepsiCare).
Proof-of-Concept LOTTO project (Grant No CONCEPT/0618/0038).
“Supported by grant and program partners including Horizon 2020 (EU), Cyprus Research and Innovation Foundation; listed supporters/partners include Gravity Ventures / Gravity Incubator, EIT Health, and European Innovation Council.”